| Quantifying the effect of the surrogate marker by information gain. | |
| | |
MedLine Citation:
|
PMID: 17825025 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Statistical validation of a surrogate marker has been studied for more than a decade. Recently, Alonso et al. (2004, Biometrics 60, 724-728) proposed a quantity called the likelihood reduction factor (LRF) to evaluate the validity of a surrogate marker. However, as pointed out in the present article, the LRF may not correctly validate a surrogate marker. Therefore, a new quantity, the proportion of information gain (PIG) using the Kullback-Leibler information, is proposed. Simulations show that under some model assumptions, the PIG precisely reflects the role of a surrogate marker. |
| | |
Authors:
|
Yongming Qu; Michael Case |
Related Documents
:
|
17427035 - A mixture model approach to the mapping of qtl controlling endosperm traits with bulked... 18924135 - Bivariate association analyses for the mixture of continuous and binary traits with the... 19788745 - Linear models for joint association and linkage qtl mapping. 20374235 - The essence of linkage-based imprinting detection: comparing power, type 1 error, and t... 1880275 - Additive and nonadditive genetic variance in female fertility of holsteins. 19963785 - Comparative analysis of phase difference estimation methods quantifying asynchronies be... |
Publication Detail:
|
Type: Comment; Journal Article |
Journal Detail:
|
Title: Biometrics Volume: 63 ISSN: 0006-341X ISO Abbreviation: Biometrics Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-09-10 Completed Date: 2007-10-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370625 Medline TA: Biometrics Country: United States |
Other Details:
|
Languages: eng Pagination: 958-62; author reply 962-3 Citation Subset: IM |
Affiliation:
|
Eli Lilly and Company, Indianapolis, Indiana 46285, USA. qu_yongming@lilly.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biometry
/
methods* Clinical Trials as Topic / statistics & numerical data* Endpoint Determination / statistics & numerical data* Humans Interferon Type I, Recombinant / therapeutic use Likelihood Functions Macular Degeneration / drug therapy, physiopathology Meta-Analysis as Topic* Models, Statistical Visual Acuity / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Interferon Type I, Recombinant |
| Comments/Corrections | |
Comment On:
|
Biometrics. 2004 Sep;60(3):724-8
[PMID:
15339295
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Imputation approaches for estimating diagnostic accuracy for multiple tests from partially verified ...
Next Document: Pax6 transcription factor is required for the interkinetic nuclear movement of neuroepithelial cells...